Celltech CDP870 partner
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Celltech is in "advanced discussions with prospective partners" for its tumor necrosis factor inhibitor CDP870, "with a view to entering a new collaboration agreement during the second quarter of 2004," the firm announces March 31. Pfizer returned full rights to Celltech earlier this year; the deal had originated with Pharmacia in 2001...